{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-006718","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.871161+00:00","generated_at":"2026-05-16T00:35:21.502024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis FY2025 total revenue $944M (+34% YoY); guides 2026 rev $800-825M, op loss $500-550M","bullets":["FY2025 total revenue $944M (2024: $705M); Q4 revenue $203M.","TRYNGOLZA net sales $108M in first launch year; DAWNZERA $7M in first full quarter.","SPINRAZA royalties $212M, WAINUA royalties $49M; collaborative rev $508M incl $280M Ono upfront.","2026 guidance: revenue $800-825M, non-GAAP op loss $500-550M, cash ~$1.6B.","Olezarsen sNDA for sHTG submitted; zilganersen NDA for Alexander disease decision H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-006718","json":"https://secwatch.observer/filing/0001140361-26-006718.json","markdown":"https://secwatch.observer/filing/0001140361-26-006718.md","text":"https://secwatch.observer/filing/0001140361-26-006718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036126006718/0001140361-26-006718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036126006718/ef20066495_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:35:21.502024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}